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Objective: Inadequate asthma control may affect asthma resource use and treatment charges, 
consequently contributing to the growing economic burden of asthma. The study objective 
was to determine the impact of medication adherence and asthma control on resource use and 
charges in mild asthmatic patients treated with inhaled corticosteroids (ICSs).
Research design and methods: A claims database was analyzed retrospectively from 
  October 2001–December 2007 to identify mild asthmatic patients aged 12–65 years who 
began ICS   treatment. Demographics, drug utilization, and resource use for each patient were 
  identified for the 365-day period before and after the index date (pre-index and post-index 
periods, respectively). Patients were designated as having high control high adherence (HCHA) 
or low control low adherence (LCLA) based on post-index exacerbations and the percentage 
of days covered; not all patients who qualified for study inclusion met adherence designation 
requirements. Differences between the HCHA and LCLA cohorts in resource use (eg, asthma 
treatment days) and asthma-related treatment charges were assessed.
Results: Compared with the HCHA cohort (n = 483), the LCLA cohort (n = 258) had more 
asthma treatment days (2.9 vs 3.9, respectively; P , 0.0001) and higher overall asthma   treatment 
charges ($2655 vs $3345, respectively; P , 0.0001) in the post-index period. An adjusted 
odds ratio suggested that patients receiving mometasone furoate (MF) were   approximately 
5 times more likely to belong to the HCHA cohort than patients receiving any other ICS 
(P , 0.0001).
Conclusions: Better asthma control and adherence to prescribed ICSs are associated with 
lower asthma-related resource use and charges. Mild asthmatic patients receiving MF were 
more likely to be in the HCHA cohort than patients receiving other ICSs, perhaps due to the 
once-daily dosing of MF. Current NAEPP guidelines recommend low-dose ICS monotherapy 
for mild persistent asthma; thus, it is critical to optimize mild persistent asthma control and 
limit unnecessary resource use and charges.
Keywords: adherence, asthma control, beclomethasone dipropionate, budesonide, fluticasone 
propionate, mometasone furoate, retrospective claims analysis
Introduction
The goal of asthma treatment is to achieve and maintain adequate asthma control, 
which can be measured by assessing the severity of asthma symptoms, the incidence of 
asthma-related exacerbations, and patient quality of life.1 Current National Asthma Edu-
cation and Prevention Program (NAEPP) guidelines define asthma control as reduced 
impairment (eg, prevention of chronic asthma symptoms and infrequent [#2 days per 
week] use of short-acting β2-agonist [SABA] rescue medication) and reduced risk 
(eg, prevention of recurrent asthma exacerbations and minimization of the need for  Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
198
Navaratnam et al
emergency department [ED] visits).1 Inadequate asthma 
control may directly affect asthma resource use and treatment 
charges, which has the potential to significantly affect the 
growing global economic burden of asthma.2 For example, 
uncontrolled asthma leads to increased use of SABAs and 
oral corticosteroids (OCSs) as well as increased ED,   hospital, 
and outpatient visits,3,4 and has been shown to correlate 
with higher asthma-related direct medical   expenditures and 
indirect charges.3 In particular, the cost of rescue SABA 
therapy has recently increased because of new US Food 
and Drug Administration regulations that eliminate the use 
of ozone-depleting chlorofluorocarbon (CFC)   propellants 
in all metered-dose inhalers (MDIs).5 Although this new 
regulation is environmentally important, it has resulted in 
the replacement of generic CFC SABA inhalers with more 
costly non-generic hydrofluoroalkane (HFA) inhalers and has 
increased the economic burden associated with overreliance 
on SABAs. In 2004, the average cost of a HFA albuterol MDI 
across all payer types was 2.9 times greater than a generic 
CFC albuterol MDI ($39.50 vs $13.50, respectively).5
One key element in achieving asthma control and 
thereby reducing healthcare utilization and costs, is proper 
adherence to prescribed asthma treatment.1 Nonadherence 
to medical treatment regimens is estimated to cost the US 
healthcare system $100 billion annually.6 Among patients 
with asthma, reduced adherence to prescribed medication 
has been   associated with the need for increased medical 
care and reduced asthma control, including increased ED 
visits, increased OCS use, increased exacerbations, and/or 
worse asthma symptom scores.7–10 Because current NAEPP 
  guidelines indicate that low-dose inhaled corticosteroids 
(ICSs) are the recommended treatment for mild persistent 
asthma,1 ICS monotherapy is the most important type of 
treatment to consider for assessing the association between 
adherence and mild persistent asthma control. Factors that 
may affect adherence for patients with mild persistent 
asthma include ease and frequency of ICS administration 
and patients’ perceptions of treatment effectiveness.   Previous 
data indicate that patients with asthma are more likely to 
be highly adherent to once-daily ICS therapy compared 
with twice-daily ICS therapy.11 However, adequate formal 
analyses of the difference in charges and resource utilization 
of ICS treatment between highly adherent and minimally 
adherent patients with mild asthma are lacking from the 
current biomedical literature.
The primary objective of the current study was to 
determine the impact of adherence and asthma control on 
resource use and asthma treatment charges in patients with 
mild asthma having ICS claims. A secondary objective 
was to determine which ICS treatment was associated with 
the greatest likelihood of achieving high control and high 
  adherence, which may indicate which ICS therapies are best 
for optimizing asthma control.
Patients and methods
study design
A claims database (Ingenix LabRx, Eden Prairie, MN, USA) 
was analyzed retrospectively from October 2001 through 
December 2007 to identify patients with mild asthma who 
began treatment with an ICS, including but not limited to 
mometasone furoate (MF; Asmanex®, Merck & Co., Inc., 
Whitehouse Station, NJ, USA), fluticasone propionate (FP; 
Flovent®, GlaxoSmithKline, Research Triangle Park, NC, 
USA), FP HFA (Flovent® HFA, GlaxoSmithKline, Research 
Triangle Park, NC, USA), budesonide (Pulmicort®, Astra-
Zeneca LP,   Wilmington, DE, USA), or beclomethasone 
dipropionate (Qvar®, 3M Drug Delivery Systems, Northridge, 
CA, USA). During the timeframe used for this analysis, the 
database included approximately 37 million patients who 
primarily resided in the Southern or Midwestern United 
States (South, 43%; Midwest, 33%; West, 13%; Northeast, 
11%). For each patient, the date of the first ICS prescription 
fill was considered the index date. Demographic information, 
drug utilization, and resource use for each patient were identi-
fied for the 365-day period before the index date (pre-index 
period) and the 365-day period following the index date (post-
index period).   Information collected during the pre-index 
period included total number of SABA canister prescriptions 
filled; incidence of   comorbidities, including pneumonia, 
sinusitis, acute bronchitis, acute laryngitis, upper respiratory 
infection, acute nasopharyngitis, gastroesophageal reflux 
disease, and   rhinitis; total asthma-related charges; pre-index 
asthma days; and pre-index asthma records. Asthma days was 
defined as the number of distinct days in which the patient 
had a medical record with any diagnosis of asthma in the 
pre-index period. Pre-index asthma records was defined as 
the number of   distinct asthma-related records, identified by 
the presence of an asthma-related International Classification 
of Diseases, 9th Edition, Clinical Modification (ICD-9-CM) 
code in which the patient had a medical record with a diag-
nosis of asthma in the pre-index period; note that a single 
office visit may have resulted in .1 asthma record.
Patients
All patients met the following inclusion/exclusion criteria: 
received an ICS prescription between October 2001 and Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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December 2007; enrolled in health plans at least 1 year before 
and 1 year after index date; were 12 to 65 years of age; had 
no other chronic pulmonary condition (eg, identified by 
ICD-9-CM codes 415X, 416X, 417X, 491X, 491.2X, 492X, 
493.2X, 494X, or 770.2X); received no combination therapy 
within 7 days of the index date; did not switch asthma therapy 
during post-index period; were designated as having mild 
asthma using an algorithm developed previously;12 and were 
designated as having high control, high adherence (HCHA) 
or low control, low adherence (LCLA). Patients with mild 
asthma were defined as those who had been diagnosed with 
an ICD-9-CM code of 493.0X, 493.1X, or 493.9X and did not 
experience an asthma exacerbation or use .2 SABA canisters 
during the 365-day pre-index period. Although these criteria 
for mild asthma are not clinically based, similar methods have 
been used in other analyses.12–14 An asthma exacerbation was 
defined as an asthma episode that required   hospitalization, 
treatment in an emergency room, or an outpatient visit during 
which nebulization or a prescription for OCSs was given, 
as previously described.12 For adherence, the percent days 
covered (PDC) was defined as the percentage of days that 
patients had access to medication assuming daily drug use. 
The HCHA cohort included patients with no exacerbation 
events (high control) and $60% PDC (high adherence) 
  during the post-index period. The LCLA cohort included 
patients with $2 exacerbation events (low control) and 
,10% PDC (low adherence) during the post-index period. 
Low adherence was selected as ,10% PDC because this 
corresponds with patients who generally had 1 and only 1 
prescription (eg, a median 30-day supply) during the 1-year 
post-index period. These cutoffs were based on distributions 
of exacerbations and PDC using upper and lower quartiles 
(eg, no priori determinations were made regarding patient 
cutoff points for designation as HCHA or LCLA).
Assessments
The primary outcomes of this analysis were post-index 
comparisons between the HCHA and LCLA cohorts in 
asthma-related resource use (eg, asthma-related medical 
records, asthma treatment days, and OCS claims) and charges 
(eg, outpatient charges, inpatient charges, pharmaceutical 
charges, and total asthma charges). All asthma charges were 
adjusted to 2008 US dollars.
Secondary outcomes of this analysis included the 
  percentage of patients in each ICS treatment group who 
belonged in the HCHA cohort and odds ratios for the 
  likelihood of belonging to the HCHA cohort based on ICS 
treatment initiated on the index date. This analysis was 
  limited to ICSs for which patient sample sizes in the database 
were $500.
statistical analyses
Bivariate analyses of the HCHA and LCLA cohorts were 
  performed to determine differences in asthma resource use 
and overall asthma treatment charges. A 2-by-2   contingency 
table chi-square analysis was preformed to compare the 
u  nadjusted odds of patients belonging to the HCHA cohort 
based on ICS treatment. A forward stepwise logistic 
  regression model was built to evaluate the odds ratio of a 
patient on a specific ICS therapy belonging to the HCHA 
cohort, adjusting for other covariates in the model.
Results
A total of 741 patients were included in the current analysis 
(Figure 1). Because this analysis was designed to   compare 
patients at the extreme ends of the adherence/control 
  spectrum, only 4% of patients who met all other inclusion/
exclusion criteria qualified for either the HCHA or LCLA 
cohort (Figure 1). The majority of patients were female; the 
mean age of patients was 44.2 and 33.4 years in the HCHA 
and LCLA cohorts, respectively (Table 1). The HCHA cohort 
had a higher age, a lower proportion of female patients, 
a larger number of asthma days and asthma-related records, 
and higher asthma-related charges during the pre-index 
period (P , 0.0001; Table 1). Both cohorts were similar 
in the proportions of patients with measured comorbidities, 
with the exception of rhinitis (higher in the HCHA cohort 
[P , 0.0001; Table 1]) and upper respiratory tract infection 
(higher in the LCLA cohort [P , 0.0001; Table 1]).
resource use and treatment  
charges: bivariate analyses
Compared with the HCHA cohort, the LCLA cohort was 
  associated with more mean asthma-related   medical records 
(5.6 vs 9.7, respectively; P , 0.0001), more mean asthma treat-
ment days (2.9 vs 3.9, respectively P , 0.0001), more mean 
OCS prescriptions (0.0 vs 0.4, respectively; P , 0.0001), 
and fewer mean ICS records (7.7 vs 1.0,   respectively; 
P , 0.0001) in the post-index period (Figure 2).
The HCHA cohort was associated with lower total mean 
asthma charges in the post-index period compared with the 
LCLA cohort ($2655 vs $3345, respectively, P , 0.0001; 
Figure 3). Mean pharmaceutical asthma charges were 
  significantly higher for the HCHA cohort compared with 
the LCLA cohort ($1085 vs $129, respectively, P , 0.0001; 
  Figure 3), as one would expect based on the cohort   definitions.  Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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The lower overall mean asthma treatment charges in the 
HCHA cohort were primarily driven by lower resource use (ie, 
inpatient/outpatient charges) compared with the LCLA cohort 
(inpatient charge, $19 vs $1248, respectively, P , 0.0001; 
outpatient charge, $1551 vs $1968, P = 0.0001; Figure 3).
ics use associated with hchA: 
multivariate analyses
Among patients who met all inclusion criteria and received 
an ICS that was prescribed to $500 patients in the database 
(n = 16,521), a total of 450 patients belonged to the HCHA 
cohort. A significantly higher percentage of patients in 
this subanalysis who received MF belonged in the HCHA 
cohort than any other ICS (P , 0.0001; Figure 4). Using 
an unadjusted chi-square analysis, MF patients were 7.425 
times more likely than patients receiving other ICS agents 
to be in the HCHA cohort (P , 0.0001). Calculation of 
odds ratios from the logistic regression model revealed that 
patients receiving MF were 5.081 (95% CI, 4.144–6.230) 
times more likely than patients receiving other ICS agents 
to be in the HCHA cohort (P , 0.0001) after adjusting for 
all other pre-index variables.
Discussion
The results of the current analysis suggest that increases in 
asthma control and adherence to prescribed asthma medica-
tion correlate with decreases in total asthma-related charges. 
Among patients with a low level of asthma control, who 
were minimally adherent to their prescribed ICS medication, 
the incidence of asthma-related records, asthma treatment 
days, and the number of OCS prescriptions were higher 
compared with patients who had a superior level of asthma 
control and were more adherent to their prescribed ICS 
medication. This finding is not surprising given the strong 
correlation between asthma patient adherence to prescribed 
medication and asthma control,7–10 and the increased costs 
associated with asthma exacerbations15 and/or extra doctor 
visits16 that often accompany poorly controlled asthma. In a 
large retrospective analysis of a managed care database by 
Stern and colleagues (N = 97,743), patients who were more 
highly compliant to their prescribed controller medication 
(including ICSs) were significantly less likely to experience 
an asthma-related exacerbation (P , 0.001).9 Other studies 
Inclusion/Exclusion
Criterion Sample Size, n
Asthma patients with an 
ICS prescription identified
554,334
Enrolled  ≥ 1 y before and  
≥ 1 y after index date 
117,729
12–65 y of age 66,798
No other chronic 
pulmonary condition 54,826
No combination therapy 
within 7 d of index date
30,599
Did not receive treatment with the 
therapy of another treatment cohort 
within 7 days of index date*
29,865
Did not switch asthma therapy 
during postindex period
24,998
Characterized as having 
mild asthma
18,194
741
Belonged to only 1 
treatment cohort*
23,950
Characterized as belonging to 
the LCLA or HCHA subgroups
LCLA, 
n = 258
HCHA, 
n = 483
Figure 1 Patient selection. Patients were identified from a commercial insurance 
database and analyzed retrospectively to identify those with mild asthma who initiated 
treatment with an ics. Patients who met all inclusion and exclusion criteria were 
assigned to 1 of 2 control/adherence cohorts based on the number of exacerbation 
events and percent days covered in the pre-index period: hchA, 0 exacerbation 
events and $60% PDc; LcLA, $2 exacerbation events and ,10% PDc.
Abbreviations: ics, inhaled corticosteroid; hchA, high control high adherence; 
LcLA, low control low adherence; PDc, percent days covered. 
*criterion included owing to the initial existence of a fluticasone propionate with 
salmeterol cohort, which is not presented in the current analysis.
Table 1 Demographics and characteristics at index date 
Demographic or 
characteristic
HCHA 
(n = 483)
LCLA 
(n = 258)
P value
Mean age, y 44.2 33.4 ,0.0001
Female, % 61.5 76.4 ,0.0001
Mean sABA claims, n 0.50 0.56 0.1844
Asthma days, n 1.7 1.0 ,0.0001
Pre-asthma records, n 3.7 1.8 ,0.0001
Mean asthma-related charges, $ 502 297 ,0.0001
comorbidity, %
  rhinitis 48.0 30.2 ,0.0001
  sinusitis 27.5 29.8 0.5065
  Upper respiratory infection 15.5 31.4 ,0.0001
  Acute bronchitis 15.5 18.6 0.2836
  gerD 14.1 11.2 0.2752
  Pneumonia 2.3 4.3 0.1291
  Acute laryngitis 1.7 2.3 0.5238
  Acute nasopharyngitis 1.9 1.6 0.7572
Abbreviations: gerD, gastroesophageal reflux disease; HCHA, high control high 
adherence; LcLA, low control low adherence; sABA, short-acting β2-agonist.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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that specifically assessed adherence to ICS treatment have 
found that enhanced patient adherence is associated with 
increased asthma control as measured by overall asthma 
control scores,7,8 emergency department visits,10 and OCS 
prescriptions.10 In a prospective cohort study by   Krishnan 
and colleagues (N = 60), asthma patients with poor adher-
ence had significantly worse asthma symptom scores 
(P = 0.04) 2 weeks after hospital discharge following an 
asthma   exacerbation.7 In a large, descriptive, observational 
study by Molimard and Le Gros (N = 4362), asthma control 
was deemed inadequate among 62.7% of persistent asthma 
patients who missed $4 ICS doses per week, but only 
37.5% of patients who missed ,4 ICS doses per week.8 In a 
retrospective claims database analysis of asthma patients by 
Williams and colleagues (N = 405), ICS adherence correlated 
negatively and significantly to emergency department visits 
and OCS prescriptions; furthermore, each 25% increase in 
the percentage of time that patients were without ICS therapy 
doubled the asthma-related hospitalization rate.10
The lower asthma-related days and records observed 
in the HCHA cohort compared with the LCLA cohort is in 
contrast to the index date data, when these parameters were 
higher in the HCHA cohort. This may suggest subjects in the 
HCHA cohort had slightly more severe (although still mild) 
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asthma resulting in more asthma-related visits. The resulting 
decrease in asthma-records and days during the post-index 
period may be due to implementation of ICS   treatment 
  resulting in control (prior ICS use was not part of the 
  inclusion criteria), a switch to more effective therapy, or an 
emphasis on drug adherence by the prescribing physician.
Collectively, these data demonstrate that enhanced 
  adherence to prescribed ICS therapy correlates with 
improved asthma control. As such, it is critical to optimize 
patient   adherence to not only improve patient outcomes, but 
also to lower the global economic burden of asthma care. 
The increased asthma-related exacerbations,   emergency 
room visits, and inpatient and outpatient doctor visits 
  associated with poorly controlled asthma result in   significant 
  pharmacoeconomic burden.15,16 A recent retrospective analy-
sis of the 2004 Medical Expenditure Panel Survey data by 
Kamble and Bharmal estimated that asthma afflicts 6.4 million 
children and 14.8 million adults in the United States alone 
and costs approximately $1000 and $2000, respectively, per 
person annually in 2007 US dollars.16 All medical visits com-
bined (including inpatient, outpatient, emergency room, and 
office-based medical visits) accounted for approximately 60% 
of all asthma-related expenditures in children and approxi-
mately 40% of all asthma-related expenditures in adults. 
Given the significant overall   economic burden of asthma and 
the association between asthma control and patient adherence 
to prescribed medication,   improvements in patient adherence 
and asthma control have the potential to significantly reduce 
asthma-related healthcare expenditures.
As expected, data from the current study suggested 
that reduced asthma control and adherence to prescribed 
asthma medication correlated with increased asthma-related 
total charges driven by increased inpatient and outpatient 
charges. Previous studies have demonstrated similar cor-
relations between asthma control, adherence, and resource 
use and charges. Among asthma patients (N = 527) strati-
fied to 1 of 4 quartiles of asthma control that ranged from 
“good control” to “poor control,” Accordini and colleagues 
found that   hospitalizations and doctor visits increased 
significantly with decreasing levels of controller medica-
tion use and poor asthma control, and generally correlated 
with higher   asthma-related direct medical expenditures 
and indirect costs.3 For all 5 mean annual cost parameters 
assessed (ie, doctor visits and lab visits, pharmacological 
treatment,   hospitalization, indirect costs, and total), the 
estimated mean annual cost per patient increased as the 
level of disease c  ontrol decreased (P , 0.001).3 In   parallel 
with results from the   current study, patients with poor 
asthma control experienced the lowest   percentage of direct 
charges due to   pharmacological   treatment and the highest 
percentage of direct charges due to hospitalization, whereas 
patients with good asthma   control experienced notably higher 
  pharmacological treatment charges and lower direct charges.3 
Collectively, these data suggest that the total expenses associ-
ated with asthma-related charges are lower for patients with 
superior asthma control, driven by reductions in hospital and 
physician-related   services (ie, inpatient and outpatient visits, 
hospitalizations, and ED visits) charges, but not reductions 
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in prescription medication charges. This finding is somewhat 
surprising because the greatest contributor to asthma care 
charges in the United States is prescription drugs, which are 
estimated to account for 43% of the $16.1 billion spent on 
asthma care annually.17 However, it is possible that minimally 
adherent patients with mild persistent asthma who have 
poorly controlled asthma have lower pharmaceutical asthma-
related charges because they do not adhere to their prescribed 
dosing regimens of controller medications, such as ICSs. As 
such, these patients may use less of their   prescribed medica-
tion, which may lead to complications that result in asthma 
exacerbations, hospitalizations, ER visits, and/or more fre-
quent trips to see physicians. The current data   suggest that 
highly adherent asthma patients who achieve a high level 
of asthma control may have more charges for prescription 
medication than patients with a lower level of adherence 
and asthma control, but the tradeoff for this higher expense 
is fewer inpatient and outpatient physician visits, which cor-
responds with lower total medical care charges.
There are several reasons why patients who received 
MF were approximately 5 times more likely to be in the 
HCHA cohort than patients who received the other ICSs. In 
general, there are limited data that suggest clinically relevant 
differences between ICSs in clinical efficacy.18 However, 
study outcomes that may be related to patient adherence (ie, 
asthma control) will tend to be minimal in well organized 
clinical trials because such trials are often designed to limit 
  differences between treatment groups in adherence. The once-
daily dosing regimen of MF may be the most likely reason 
why a higher percentage of patients receiving MF were in 
the HCHA cohort compared with patients who received one 
of the other ICSs. Previous data suggest that adherence to 
prescribed medication, regardless of disease state, increases 
as daily doses decrease.19 Guest et al specifically investi-
gated the change in adherence when patients with asthma 
were switched from a twice-daily ICS to once-daily ICS 
treatment.11 As might be expected, patients who switched to 
a once-daily ICS were more likely to be highly adherent and 
had lower asthma-related charges compared with patients 
who switched to another   twice-daily ICS dosing regimen.11 In 
addition, Price et al found that for MF specifically, adherence 
was significantly higher for   once-daily dosing than twice-
daily dosing.20 NAEPP guidelines note the importance of 
assessing and encouraging asthma patient adherence to pre-
scribed therapy,1 and point out that adherence to a therapeutic 
plan is enhanced when daily doses are minimized.21–23 Further 
analyses in larger sample sizes of patients are necessary to 
verify if MF treatment is associated with lower asthma-related 
charges among highly adherent, high asthma control patients 
compared with other ICSs because of a superior dosing 
regimen. Furthermore, it is important to note that although 
most patients with asthma treated with MF are prescribed 
a once-daily dosing   regimen, some patients (ie, those $12 
years of age   receiving oral OCSs) may receive a twice-daily 
regimen,24 and it is impossible to determine how many 
patients were prescribed once-daily MF versus   twice-daily 
MF in the current claims database analysis. However, because 
of their designation as mild asthma patients, it is likely that 
the majority of patients in the current study who received 
MF were prescribed a once-daily regimen.
An alternative or additional explanation for the increased 
adherence with MF patients is that the MF device (  Twisthaler®, 
Merck & Co., Inc., Whitehouse Station, NJ, USA) is easy 
to use. There are only 3 steps in the dosing process and the 
device has an integrated dose   counter.25 In a head-to-head 
comparison of the MF Twisthaler and a fluticasone propionate 
metered-dose inhaler, there was no significant difference in 
the number of subjects who rated the inhalers “easy to use,” 
but significantly more subjects using Twisthaler “liked it a lot” 
(47% vs 22%, P = 0.01).26 Ease of use and patient satisfaction 
with an inhaler may contribute to adherence, but this area of 
research has not been adequately explored.
One limitation of the overall design of the current 
study was that it only included patients with a low level 
of asthma control and adherence to their prescribed ICS 
medication, or a high level of asthma control and adherence 
to their   prescribed ICS medication. In real-world clinical 
settings, many asthma patients fall somewhere in between 
this   continuum, with “medium” levels of both asthma con-
trol and adherence to therapy. Previous data suggest that, 
regardless of asthma severity, improved asthma control is 
associated with lower asthma-related healthcare costs3 and 
higher patient a  dherence to prescribed therapy.7–10 However, 
  specific   analyses of patients with a low level of asthma control 
and good   adherence to prescribed therapy, or a low level of 
asthma control and poor adherence to prescribed therapy are 
lacking from the biomedical literature. One reason for this 
gap in the literature may be because it is rare to find patients 
who are not misdiagnosed who have unparalleled levels of 
asthma control and adherence to therapy. For all patients, 
physicians should promote adherence to prescribed treatment 
in accordance with current NAEPP guidelines1 to optimize 
each individual patient’s respective asthma control potential 
and minimize healthcare costs. For patients with a low level 
of asthma control who are highly adherent to their prescribed 
therapy, it may be necessary for physicians to re-evaluate the  Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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treatment plan being employed to determine if alternate 
therapeutic options should be pursued.
There are several limitations to this type of observational 
claims database analysis. The retrospective nature of the 
study limited the amount and type of information that could 
be collected, such as information about why a specific ICS 
was chosen or how adherence could be measured. Also, it 
is difficult to accurately categorize asthma severity without 
using predefined clinical outcome measures;13 one previous 
claims-based analysis categorized patients as having mild 
asthma less frequently than did pulmonary function testing in 
the same population.14 In addition, the definitions of HCHA 
and LCLA used in this analysis were not standardized and 
it is difficult to verify the accuracy of data found in a claims 
database. However, these limitations are inherent to any 
claims database analysis and do not preclude the   development 
of important and clinically relevant conclusions about the 
effect of asthma control and adherence on asthma-related 
charges and resource use.
Conclusions
Collectively, these data suggest that better asthma control 
and adherence to prescribed ICSs are associated with 
lower   overall asthma-related resource use and charges. 
Furthermore, patients with mild asthma receiving MF were 
more likely to be in the HCHA patient cohort than patients 
receiving a different ICS, which may have been due to the 
once-daily dosing regimen of MF. Of critical importance 
to optimizing mild persistent asthma control and limit-
ing asthma-related resource use and charges is following 
current NAEPP guidelines, which indicate low-dose ICS 
monotherapy as the preferred treatment for mild persistent 
asthma.1
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